Dr. Nizar Tannir, a specialist in genitourinary cancer at the Houston center, said that before 2005 there was not much to offer patients with advanced renal cell carcinoma. But within two years, three new drugs became available that have resulted in a 50 percent increase in overall survival.
Sixth Annual Penn State Uplifting Athletes "Lift For Life" Set for July 11 to Benefit the Kidney Cancer Association
During its first five years, Penn State Football Uplifting Athletes' "Lift For Life®" has experienced tremendous growth. More than $230,000 has been raised for the Kidney Cancer Association.
Oncologist, Wolfram Samlowski with Nevada Cancer Institute, says it was recently discovered that kidney cancers contain a protein known as CD-70. The theory is by targeting that protein with a new drug made of human antibodies, a cancer-killing immune-response will follow.
Additionally, the report finds that the incidence of renal cell carcinoma in China was 29,000 cases in 2007. This figure will exceed 57,000 by 2017 in part due to urbanization, changes in population demographics and increases in risk factors such as obesity.
Immutep Reports that LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy in Preclinical Studies
Four new Phase I/II clinical trials are in progress: in metastatic renal cell carcinoma with IMP321 injected alone, in metastatic breast cancer combining IMP321 with paclitaxel in a chemo-immunotherapy protocol, a disease-free melanoma study with IMP321 as an adjuvant to peptide antigens and a lympho-depletive/adoptive transfer metastatic melanoma study.
Can patients afford to shop around for surgeons? How safe is surgical delay for renal cell carcinoma?
Solid renal parenchymal lesions with a diameter of 5 cm or less can be difficult to diagnose, requiring irradiation and biopsy. Catching renal cell carcinoma in early stages before tumors grow larger than 7 cm, however, increases a patient's chances of survival over five years.
In desperation, he offered to pay for the treatment. But he was told if he did so, he would also have to foot the bill for the rest of his treatment, which he could not afford.
The report also finds that three emerging targeted therapies- GlaxoSmithKline's Armala, Pfizer's axitinib and Novartis's everolimus-will launch over the next decade and will achieve significant uptake in the second- line patient segment through 2017.
TargetmTOR.com is a new Web site for healthcare professionals. It provides the most current information on the mammalian Target Of Rapamycin (mTOR), an important new therapeutic target in cancer. The site is sponsored by Novartis Oncology, a leader in mTOR research.